Diabetes Laboratory Immunoassays Market, By Type (Blood Test, Glucose Tolerance Test, Glycated Hemoglobin Determination, Insulin Assay, and C Peptide Assay), By Application (Hospital, Clinic, and Research Center), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Diabetes Laboratory Immunoassays are widely used in detecting insulin, C-peptide, HbA1c, and autoantibodies to beta cell proteins, that are important & essential biomarkers used in diagnosis and classification of diabetes.

The target market is segmented based on Type, Application, and Region.

Type Insight

On the basis of Type, the target market is segmented into Blood Test, Glucose Tolerance Test, Glycated Hemoglobin Determination, Insulin Assay, and C Peptide Assay.

Application Insight

On the basis of Application, the target market is segmented into Hospital, Clinic, and Research Center.

Regional Insights:

On region the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America market is estimated to witness a significantly high revenue share over the forecast period.·        

• Growing geriatric population coupled with increased incidence of diabetes.
• Continuous technological development.
• Growing adoption of point-of-care testing.
• Rising awareness regarding early detection of diabetes.

Asia Pacific market is estimated to witness a fastest revenue share over the forecast period.       

• Rapidly growing population and increased prevalence of diabetes.
• Improved healthcare infrastructure.
• Growing number of players operating in medical diagnostic industry in expanding markets such as India and China.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032.

The key players operating the target market includes, Bayer AG, Jei Daniel Biotech Corp., Becton Dickenson, Acon Laboratories, Inc., Beckman Coulter, Inc., Immunoshop India Pvt.  Ltd., Institute of Isotopes Co. Ltd., Instrumentation Laboratory Co., Abbott Diagnostics, Qqlab Llc., and Others.

The New Launched Product News,

• In July 2023, Wondfo launched new time-resolved fluorescence immunoassay analyzers at 2023 AACC Annual Scientific Meeting + Clinical Lab Expo. The new product includes, Accre CLIA Analyzer (A90), Finecare FIA Meters (FS-114/FS-205), and Blood Gas Analyzer (BGA-102). The Finecare FIA Meters (FS-114/FS-205) are used to analyze the conditions such as diabetes, COVID-19, cardiovascular disease, tumor, renal injury, and other.
• In November 2022, LumiraDx continued its commercial expansion of rapid microfluidic immunoassay HbA1c test. The new LumiraDx HbA1c test is designed to address rising clinical need for reliable & accessible HbA1c testing in community-based healthcare settings such as diabetes clinics, primary care, rural clinics, decentralized healthcare settings and retail pharmacy.

Strategic Acquisition News,

• In September 2023, Abbott signed an agreement for acquisition of Bigfoot Biomedical a developer of smart insulin management systems for an individual with diabetes. Bigfoot Unity a small insulin management system features connected insulin pen caps which use healthcare provider instructions and use integrated continuous glucose monitoring (iCGM) data.